| Literature DB >> 32607129 |
Morag Tolvi1, Hanna Tuominen-Salo2, Mika Paavola3, Kimmo Mattila4, Leena-Maija Aaltonen1, Lasse Lehtonen5.
Abstract
BACKGROUND: While previous studies have evaluated the effect of some patient characteristics (e.g. gender, American Society of Anesthesiologists (ASA) class and comorbidity) on outcome in orthopedic and hand day surgery, more detailed information on anesthesia related factors has previously been lacking. Our goal was to investigate the perioperative factors that affect overstay, readmission and contact after day surgery in order to find certain patient profiles more prone to problemed outcomes after day surgery.Entities:
Keywords: Contact; Day surgery; Overstay; Readmission; Revisit
Year: 2020 PMID: 32607129 PMCID: PMC7320581 DOI: 10.1186/s13037-020-00249-3
Source DB: PubMed Journal: Patient Saf Surg ISSN: 1754-9493
Table of day surgery procedures
| Decompression of median nerve, ACC51 | 167 | 96.5 |
| Discission of sheath of tendon of wrist or hand, NDM40 | 46 | 97.9 |
| Decompression of ulnar nerve, ACC53 | 43 | 97.7 |
| Palmar fasciotomy of hand, NDM10 | 42 | 100 |
| Incomplete excision of soft tissue tumor of wrist or hand, NDR20a | 36 | 92.3 |
| Arthroplasty of first CMC joint, NDG60 | 34 | 89.5 |
| Excision of synovial ganglion of wrist or hand, NDM20 | 25 | 100 |
| Fusion of DIP joint, NDG76 | 23 | 95.8 |
| Open operation for osteochondritis of joint of wrist, NDF25 | 22 | 95.7 |
| Arthroscopic exploration of joint of wrist or hand, NDA30 | 18 | 81.8 |
| Radical excision of soft tissue tumor of wrist or hand, NDR30a | 17 | 89.5 |
| Partial fusion of wrist, NDG20 | 16 | 94.1 |
| Arthroscopic partial excision of meniscus of knee, NGD05 | 16 | 88.9 |
| Removal of internal fixation device from wrist or hand, NDU20 | 14 | 93.3 |
| Removal of internal fixation device from shoulder or upper arm, NBU20 | 12 | 85.7 |
| Plastic repair of ligament or capsule of wrist with transplant, NDE40 | 11 | 100 |
acombined to form excision of soft tissue tumor of wrist or hand group
Day surgery criteria
| Operation duration < 3 h | |
| No significant risk of respiratory tract swelling | |
| No respiratory tract anomalies | |
| No or stable chronic disease | |
| No obstructive sleep apnea | |
| Body mass index < 35 | |
| Ability to climb more than 2 flights of stairs without stopping | |
| Ability to care for oneself independently | |
| No unstable psychiatric illnesses | |
| No drug or alcohol addiction | |
| Caregiver over the age of 16 at home for first postoperative night |
Patient demographics in 542 day surgery procedures
| 471 | 55 | 16 | |
| 37.4 | 58.2 | 56.3 | |
median (range) | 53.8 (16.2–92.5) | 54.3 (23.2–72.2) | 42.2 (21.1–63.3) |
median (range) | 2 (1–4) | 2 (1–4) | 1 (1–3) |
| Local (%) | 42.7 | 10.9 | |
| Regional (%) | 49.7 | 65.5 | 93.7 |
| General (%) | 7.6 | 23.6 | 6.3 |
Patient related factors and their effect on postoperative outcome in OHS day surgery
| 542 | 0.043 | ||
| Male | 217 | 9 (4.1) | |
| Female | 325 | 28 (8.6) | |
| 542 | 0.465 | ||
| 16–44 | 153 | 9 (5.9) | |
| 45–64 | 292 | 20 (6.8) | |
| 65–74 | 68 | 4 (5.9) | |
| 75+ | 29 | 4 (13.8) | |
| 542 | 0.422 | ||
| < 20 | 29 | 1(3.4) | |
| 20–24.9 | 183 | 8 (4.4) | |
| 25–29.9 | 176 | 16 (9.1) | |
| 30.0–34.9 | 102 | 9 (8.8) | |
| 35–39.9 | 32 | 1 (3.1) | |
| 40–44.9 | 16 | 2 (12.5) | |
| 45–49.9 | 3 | 0 (0) | |
| 50–54.9 | 1 | 0 (0) | |
| 539 | 0.226 | ||
| 1 | 176 | 9 (5.1) | |
| 2 | 228 | 13 (5.7) | |
| 3–4 | 135 | 13 (9.6) | |
| 542 | 0.96 | ||
| yes | 203 | 14 (6.9) | |
| no | 339 | 23 (6.8) | |
| 541 | 0.683 | ||
| no | 525 | 36 (6.9) | |
| warfarin | 8 | 1 (12.5) | |
| aspirin | 6 | 0 (0) | |
| NOAC | 2 | 0 (0) | |
| 542 | 0.17 | ||
| yes | 61 | 7 (11.5) | |
| no | 481 | 30 (6.2) | |
| 542 | 0.413 | ||
| yes | 60 | 2 (3.3) | |
| no | 482 | 35 (7.3) | |
| 542 | 0.386 | ||
| yes | 20 | 0 (0) | |
| no | 522 | 37 (7.1) | |
| 542 | 0.576 | ||
| yes | 12 | 1 (8.3) | |
| no | 530 | 36 (6.8) | |
| 542 | 0.512 | ||
| yes | 41 | 4 (9.8) | |
| no | 501 | 33 (6.6) | |
| 542 | 1 | ||
| yes | 3 | 0 (0) | |
| no | 539 | 37 (6.9) | |
| 542 | 0.639 | ||
| yes | 20 | 2 (10.0) | |
| no | 522 | 35 (6.7) | |
| 542 | 0.837 | ||
| yes | 118 | 7 (5.9) | |
| no | 424 | 30 (7.1) | |
| 534 | 0.549 | ||
| no | 378 | 22 (5.8) | |
| yes | 140 | 12 (8.6) | |
| quit | 12 | 1 (8.3) | |
| sometimes | 4 | 0 (0) |
BMI Body mass index, ASA American Society of Anesthesiologists, NOAC Novel oral anticoagulant
Anesthesia and analgesia drug related factors and their effect on outcomes in OHS day surgery
| 539 | 1 | ||
| yes | 510 | 35 (6.9) | |
| no | 29 | 2 (6.9) | |
| 539 | 0.423 | ||
| yes | 339 | 21 (6.2) | |
| no | 200 | 16 (8.0) | |
| 539 | 0.391 | ||
| yes | 226 | 18 (8.0) | |
| no | 313 | 19 (6.1) | |
| 539 | 0.064 | ||
| 0–10 | 525 | 34 (6.5) | |
| > 10 | 14 | 3 (21.4) | |
| 539 | 0.00 | ||
| 0–0.15 | 502 | 29 (5.8) | |
| > 0.15 | 37 | 8 (21.6) | |
| 539 | 0.005 | ||
| no | 527 | 33 (6.3) | |
| NSAID (ketoprofen) | 1 | 0 (0) | |
| paracetamol | 3 | 2 (66.7) | |
| other strong analgesic (alfentanil, esketamine) | 8 | 2 (25.0) | |
| 542 | 0.036 | ||
| yes | 48 | 7 (14.6) | |
| no | 494 | 30 (6.1) | |
| 542 | 0.117 | ||
| no | 476 | 29 (6.1) | |
| general anesthesia | 55 | 7 (12.7) | |
| sedation | 11 | 1 (9.1) | |
| 542 | 1 | ||
| yes | 1 | 0 (0) | |
| no | 541 | 37 (6.8) | |
| 542 | 0.656 | ||
| yes | 22 | 2 (9.1) | |
| no | 520 | 35 (6.7) | |
| 542 | 0.111 | ||
| yes | 45 | 6 (13.3) | |
| no | 497 | 31 (6.2) | |
| 541 | |||
| yes | 4 | 1 (25.0) | 0.247 |
| no | 537 | 36 (6.7) | |
| 540 | 0.107 | ||
| no | 519 | 33 (6.4) | |
| ondansetron 4 mg | 20 | 4 (20.0) | |
| metoclopramide 10 mg | 1 | 0 (0) | |
| 540 | |||
| yes | 21 | 4 (19.0) | 0.048 |
| no | 519 | 33 (6.4) | |
| 539 | 0.08 | ||
| no | 520 | 34 (6.5) | |
| NSAID (ibuprofen, ketoprofen) | 8 | 0 (0) | |
| paracetamol | 9 | 3 (33.3) | |
| weak opioids (paracetamol-codeine) | 1 | 0 (0) | |
| strong analgesics (esketamine) | 1 | 0 (0) |
NSAID Nonsteroidal anti-inflammatory drug, i.v. intravenous
Miscellaneous operation related factors and their effect on outcomes in OHS day surgery
| 542 | 0.835 | ||
| Hand surgery | 471 | 33 (7.0) | |
| Shoulder & elbow surgery | 55 | 4 (7.3) | |
| Lower limb surgery | 16 | 0 (0) | |
| 542 | 0.137 | ||
| neither | 488 | 30 (6.1) | |
| laryngeal mask airway | 51 | 7 (13.7) | |
| intubation | 3 | 0 (0) | |
| 542 | 0.077 | ||
| yes | 53 | 7 (13.2) | |
| no | 489 | 30 (6.1) | |
| 541 | 0.086 | ||
| yes | 166 | 16 (9.6) | |
| no | 375 | 21 (5.6) | |
| 542 | 0.456 | ||
| yes | 114 | 6 (5.3) | |
| no | 428 | 31 (7.2) | |
| 542 | 0.617 | ||
| yes | 16 | 0 (0) | |
| no | 526 | 37 (7.0) | |
| 542 | |||
| yes | 326 | 24 (7.4) | 0.544 |
| no | 216 | 13 (6.0) | |
| 542 | 1 | ||
| yes | 18 | 1 (5.6) | |
| no | 524 | 36 (6.9) | |
| 539 | 0.384 | ||
| no pain 0 | 467 | 31 (6.6) | |
| mild 1–3 | 41 | 3 (7.3) | |
| moderate 4–6 | 27 | 2 (7.4) | |
| severe 7–10 | 4 | 1 (25.0) | |
| 540 | 0.794 | ||
| yes | 66 | 5 (7.6) | |
| no | 474 | 32 (6.8) | |
| 540 | 0.959 | ||
| yes | 396 | 27 (6.8) | |
| no | 144 | 10 (6.9) |
NRS Numerical rating system
Various risk profiles for outcomes in OHS day surgery
| Female & Fentanyl ≥0.16 mg i.v. | 539 | 16 | 6.97 (2.29–21.29) | < 0.001 | 31.3% | 93.9% | 97.8% | 13.5% |
| Female & Remifentanil | 542 | 18 | 4.25 (1.33–13.64) | 0.015 | 22.2% | 93.7% | 97.2% | 10.8% |
| Fentanyl ≥0.16 mg i.v. & Remifentanil | 539 | 26 | 5.93 (2.31–15.21) | < 0.001 | 26.9% | 94.2% | 96.2% | 18.9% |
| Female & Fentanyl ≥0.16 mg i.v. & Remifentanil | 539 | 8 | 15.09 (3.61–63.06) | < 0.001 | 50.0% | 93.8% | 99.2% | 10.8% |
| Fentanyl ≥0.16 mg i.v. & General anesthesia | 539 | 30 | 4.86 (1.93–12.23) | < 0.001 | 23.3% | 94.1% | 95.4% | 18.9% |
| Fentanyl ≥0.16 mg i.v. & Plexus block | 538 | 18 | 5.87 (1.97–17.47) | 0.001 | 27.8% | 93.8% | 97.4% | 13.5% |
| Fentanyl ≥0.16 mg i.v. & Remifentanil & General anesthesia | 539 | 26 | 5.93 (2.31–15.21) | < 0.001 | 26.9% | 94.2% | 96.2% | 18.9% |
| Female & Fentanyl ≥0.16 mg i.v. & General anesthesia | 539 | 10 | 10.02 (2.70–37.26) | < 0.001 | 40.0% | 93.8% | 98.8% | 10.8% |
| Female & Fentanyl ≥0.16 mg i.v. & Plexus block | 538 | 6 | 14.65 (2.85–75.33) | 0.001 | 50.0% | 93.6% | 99.4% | 8.1% |
| Female & Antiemetic medication | 540 | 13 | 6.65 (1.95–22.75) | 0.003 | 30.8% | 93.7% | 98.2% | 10.8% |
| Fentanyl ≥0.16 & Antiemetic medication | 539 | 14 | 2.33 (0.50–10.84) | 0.280 | 14.3% | 93.3% | 97.6% | 5.4% |
OR Odds ratio, CI Confidence interval, PPV Positive predictive value, NPV Negative predictive value, i.v. intravenous